Amicus Therapeutics, Inc. (FOLD)
Apr 27, 2026 - FOLD was delisted (reason: acquired by BMRN)
14.49
0.00 (0.00%)
Inactive · Last trade price on Apr 24, 2026
Amicus Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 214.01 | 213.75 | 246.99 | 148.81 | 245.2 |
Short-Term Investments | 79.53 | 36.19 | 39.21 | 144.78 | 237.3 |
Cash & Short-Term Investments | 293.54 | 249.95 | 286.2 | 293.6 | 482.5 |
Cash Growth | 17.44% | -12.67% | -2.52% | -39.15% | -0.16% |
Accounts Receivable | 115.31 | 101.1 | 87.63 | 66.2 | 52.67 |
Inventory | 228.82 | 118.78 | 59.7 | 23.82 | 26.82 |
Other Current Assets | 38.51 | 34.91 | 49.53 | 40.21 | 34.85 |
Total Current Assets | 676.17 | 504.74 | 483.06 | 423.82 | 596.83 |
Net Property, Plant & Equipment | 48.25 | 51.66 | 57.98 | 60.31 | 63.08 |
Other Intangible Assets | 13.92 | 17.2 | 20.49 | 23 | 23 |
Goodwill | 197.8 | 197.8 | 197.8 | 197.8 | 197.8 |
Other Long-Term Assets | 13.74 | 13.64 | 18.55 | 19.24 | 24.43 |
Total Assets | 949.87 | 785.03 | 777.88 | 724.17 | 905.14 |
Liabilities
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 28.63 | 12.95 | 15.12 | 15.41 | 21.51 |
Accrued Expenses | 200.46 | 127.3 | 144.25 | 93.64 | 98.15 |
Current Portion of Leases | 8.74 | 8.46 | 8.32 | 8.55 | 7.41 |
Other Current Liabilities | - | - | - | 21.42 | 18.9 |
Total Current Liabilities | 237.83 | 148.7 | 167.69 | 139.02 | 145.98 |
Long-Term Debt | 392.66 | 390.11 | 387.86 | 391.99 | 389.36 |
Long-Term Leases | 40.96 | 45.08 | 48.88 | 51.58 | 43.36 |
Other Long-Term Liabilities | 4.18 | 7.1 | 13.28 | 18.53 | 19.08 |
Total Long-Term Liabilities | 437.8 | 442.29 | 450.02 | 462.1 | 451.8 |
Total Liabilities | 675.63 | 590.99 | 617.71 | 601.12 | 597.77 |
Shareholders' Equity
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 3.04 | 2.94 | 2.92 | 2.82 | 2.81 |
Treasury Stock | -0.07 | - | - | - | - |
Additional Paid-in Capital | 3,014 | 2,926 | 2,836 | 2,665 | 2,596 |
Accumulated Other Comprehensive Income | 24.11 | 5.1 | 5.24 | -12.11 | 4.98 |
Retained Earnings | -2,767 | -2,740 | -2,684 | -2,532 | -2,296 |
Shareholders' Equity | 274.24 | 194.05 | 160.17 | 123.05 | 307.37 |
Total Liabilities & Equity | 949.87 | 785.03 | 777.88 | 724.17 | 905.14 |
Additional Metrics
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 442.36 | 443.64 | 445.06 | 452.12 | 440.13 |
Net Cash (Debt) | -148.83 | -193.7 | -158.86 | -158.53 | 42.37 |
Net Cash Growth | - | - | - | - | 1.99% |
Net Cash Per Share | -0.48 | -0.64 | -0.54 | -0.55 | 0.16 |
Book Value | 274.24 | 194.05 | 160.17 | 123.05 | 307.37 |
Book Value Per Share | 0.89 | 0.64 | 0.54 | 0.43 | 1.13 |
Tangible Book Value | 62.53 | -20.95 | -58.11 | -97.75 | 86.57 |
Tangible Book Value Per Share | 0.20 | -0.07 | -0.20 | -0.34 | 0.32 |